Leaps by Bayer
Profile, fund size and portfolio
Leaps by Bayer is the corporate venture arm of Bayer, a pharmaceutical and biotech company. It was founded in 2015 and is based in Berlin, Germany. It invests from seed to Series B. Sectors it names: biotech and life sciences.
Every figure links to its source
Snapshot
Data behind this graphic
| Item | Value |
|---|---|
| Stage range | Seed to Series B |
| Sectors | Biotech and life sciences |
| Geography | North America, Europe, Asia |
| Offices | Berlin, Germany, Boston, United States, Basel, Switzerland, Bay Area, United States, St. Louis, United States |
Sources: S1 Leaps by Bayer approach (archived copy 2026; live site blocks bots); S7 Leaps by Bayer Annual Review 2025 (PDF).
Data behind this graphic
| Item | Companies | Share |
|---|---|---|
| Health | 42 | 65.6% |
| Agriculture | 22 | 34.4% |
A company can carry more than one tag
Sources: S5 Leaps portfolio, health (archived copy 2025-08-03; page data feed has status, first investment date, website).
Data behind this graphic
| Measure | Value | Unit | Kind | Source |
|---|---|---|---|---|
| Headline size | USD 2.1bn+ | Cumulative invested | Stated by the firm or its parent | S1 |
| Companies backed | 65+ | companies | Stated by the firm | S1 |
| Companies on the firm's portfolio page | 64 | companies | Counted from the firm's own list | S5 |
Sources: S1 Leaps by Bayer approach (archived copy 2026; live site blocks bots); S5 Leaps portfolio, health (archived copy 2025-08-03; page data feed has status, first investment date, website).
Where it invests and who leads it
LeadersS4S2S3
- Juergen EckhardtEVP and Head of Leaps by BayerLinkedInFirm page
- Rakhshita DharHead of Health Venture InvestmentsLinkedInFirm page
- Paimun AminiVP of Agriculture Venture InvestmentsLinkedInFirm page
- Brendan KellySenior Director of Health Venture InvestmentsFind on LinkedInFirm page
- Sara OlsonSenior Director of Agriculture Venture InvestmentsLinkedInFirm page
Key facts
| Fact | Value | Status | Source |
|---|---|---|---|
| Parent company | Bayer (XETRA: BAYN) | Single source | S9 |
| Parent industry | Pharmaceuticals and biotech | Single source | S9 |
| Founded | 2015 | Single source | S7 |
| Headquarters | Berlin, Germany | Single source | S2 |
| Status | Active | Single source | S9 |
| Capital source | Parent company only | Single source | S1 |
| Headline size | USD 2.1bn+ (Cumulative invested) | Single source | S1 |
| Companies backed | 65+ | Single source | S1 |
| People on the team page | 18 | Single source | S2 |
| Stages | Seed, Series A, Series B | Single source | S1 |
Portfolio
The firm's portfolio page lists 64 companies: 48 active, 16 exited.S5
| Tag | Companies | Share |
|---|---|---|
| Active | 48 | 75% |
| Exited | 16 | 25% |
| Tag | Companies | Share |
|---|---|---|
| Health | 42 | 65.6% |
| Agriculture | 22 | 34.4% |
Every company on the Leaps by Bayer list
64 companies, as listed on the firm's own website: 48 active, 16 exited.S5 Read the firm's list.
Active 48
- 65Lab
- Ada Health
- Aferna Bio
- Affini-T Therapeutics
- AgBiome
- Amfora
- AMR Action Fund
- Andes
- Apollo Agriculture
- Atomwise
- Bloom Science
- Capstan Therapeutics
- Cellino
- ChrysaLabs
- CORXEL
- Deka Biosciences
- Dewpoint
- EarthOptics
- Edifice Health
- eGenesis
- Fork \u0026 Good
- FutuRx
- Gandeeva Therapeutics
- Grão Direto
- GRO Biosciences
- Guardian Agriculture
- Huma
- Immunitas Therapeutics
- Indapta Therapeutics
- Khloris Biosciences
- Kojin Therapeutics
- Mozart Therapeutics
- New Leaf Symbiotics
- Nextpoint Therapeutics
- NuCicer
- Nuvig Therapeutics
- Oerth Bio
- One Drop
- Pairwise
- Paratus Sciences
- Rantizo
- Recode Therapeutics
- Sound Agriculture
- Sudo Biosciences
- Triumvira Therapeutics
- Ukko
- Vesigen Therapeutics
- Woebot Health
Exited 16
- Arvinas
- Azitra
- BlueRock Therapeutics
- Boundless Bio
- Care/of
- Casebia Therapeutics
- Century Therapeutics
- Combyne
- CoverCress
- CRISPR Therapeutics
- Joyn Bio
- Metagenomi
- Pyxis Oncology
- Recursion
- Senti Bio
- Unfold
For founders
| Item | What the firm says | Source |
|---|---|---|
| Stages | Seed, Series A, Series B | S1 |
| Leads rounds | Yes | S10 |
| Beyond capital | Active incubation: team members engage in company development, providing resources and helping steer the initial direction; Portfolio companies remain autonomous with respect to decision making | S1 |
| Contact form | leaps.bayer.com/contact | S12 |
Notable outcomes
IPOs and acquisitions of portfolio companies. Price shown only where published.
Recent rounds
Investments by year
History
- Leaps by Bayer founded; first investment in CRISPR Therapeutics and co-founded Casebia.S7
- Co-founded BlueRock Therapeutics.S7
- Invested in Century Therapeutics; BlueRock Therapeutics became part of Bayer.S7
- Century Therapeutics and Recursion listed on Nasdaq.S7
- Total invested passed USD 2 billion; first Chinese investment (CORXEL).S7
- Capstan Therapeutics acquired by AbbVie for USD 2.1 billion in cash.S7
- Led Sabanto Series B (14 Jul 2026); participated in Celea Therapeutics USD 180M financing (Reuters, 2 Jul 2026).S10
About Bayer
Official pages
Read the firm's own pages for current information.
- Website leaps.bayer.com
- Portfolio leaps.bayer.com/companies/health
- LinkedIn company page www.linkedin.com/company/leapsbybayer
Sources
- S1Leaps by Bayer approach (archived copy 2026; live site blocks bots)Firm
- S2Leaps by Bayer teamFirm
- S3Leaps by Bayer team page (archived copy 2026-07-07, with LinkedIn links)Firm
- S4Juergen Eckhardt profile (leaps.bayer.com)Firm
- S5Leaps portfolio, health (archived copy 2025-08-03; page data feed has status, first investment date, website)Firm
- S6Leaps portfolio, agriculture (archived copy)Firm
- S7Leaps by Bayer Annual Review 2025 (PDF)Firm
- S8Leaps by Bayer Annual Review 2023 (PDF)Firm
- S9Bayer Half-Year Financial Report Q2 2026: Leaps by BayerParent company
- S10Sabanto and Leaps by Bayer announce Series B (PR Newswire)Portfolio company
- S11Reuters via 740 The FAN: PureTech entity Celea raises $180 millionPress
- S12Leaps by Bayer contact (archived copy)Firm
- S13Leaps by Bayer on LinkedInFirm
- S14Leaps by Bayer news page (archived copy)Firm
Disclaimer and corrections
Not affiliated. This page is not affiliated with, endorsed by or sponsored by Leaps by Bayer or any company named on it. Names and trademarks belong to their owners. Informational only. This is a public-source reference. It is not investment, legal or tax advice and not an offer or solicitation. Sources. Each figure names its source. Figures may have changed. Please read the firm's official pages, linked above. Corrections and takedown. To report an error or ask for a change or removal, use the correction form or email Richard@CorporateVentureCapital.com.
Spotted a mistake? Report a correction.